目的 探讨阿托伐他汀对急性冠脉综合征(acute coronary syndrome,ACS)患者血清基质金属蛋白酶-9(matrix metalloproteinase-9,MMP-9)、白介素-18(interleukin-18,IL-18)水平的影响。方法 将ACS患者60例随机分为阿托伐他汀组(阿托伐他汀20 mg/d,连续用药14 d)和对照组(除未用阿托伐他汀外,余治疗同阿托伐他汀组)。药物治疗前及治疗14 d后检测血清MMP-9、IL-18水平。结果 阿托伐他汀组治疗后MMP-9及IL-18 [分别是(295±110) mg/L和(399±115) pg/ml]与治疗前[分别是(368±97) mg/L和(471±105) pg/ml]比较有下降,差异均有统计学意义(P<0.05);阿托伐他汀组治疗后MMP-9及IL-18水平均明显低于同期对照组[分别是(358±95) mg/L和(466±109) pg/ml],差异有统计学意义(P<0.05)。结论 阿托伐他汀可降低 ACS 患者血清 MMP-9、IL-18水平,抑制斑块内炎性反应,促进斑块的稳定性。
Abstract
Objective To investigate the effect of atorvastatin on plasma MMP-9 and IL-18 in patients with acute coronary syndrome (ACS). Methods Sixty patients with ACS were randomly divided into treatment group (taking atorvastatin 20 mg/d for 14 days), control group (no atorvastatin, other treatments were similar to treatment group). Before drug therapy and after 14 days, MMP-9 and IL-18 levels in serum were measured. Results Compared with pre-treatment, the levels of MMP-9 and IL-18 in treatment group were decreased [(295±110)mg/L vs(358±95)mg/L;(399±115)pg/ml vs(471±105)pg/ml ,respectively],these differences were statistically significant (P<0.05). Moreover, the levels of MMP-9 and IL-18 in treatment group were significantly lower than those in control group [(358±95)mg/L,(466±109)pg/ml, respectively], these differences were statistically significant (P<0.05). Conclusions Atorvastatin can decrease serum MMP-9 and IL-18 levels in patients with ACS, which contributes to inhibit plaque inflammation, to advance the stability of plaque. Early intensive atorvastatin treatment may yield more significant benefits to the patients with ACS.
关键词
急性冠脉综合征 /
阿托伐他汀 /
基质金属蛋白酶-9 /
白介素-18
Key words
acute coronary syndrome /
atorvastatin /
matrix metalloproteinase-9 /
interleukin-18
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Davl G, Tuttolomondo A,Santilli F,et al. CD40 ligand and MCP-1 as predictors of cardiovascular events in diabetic patients with stroke[J]. J Atheroscler Thromb,2009,16( 6):707-713.
[2] Libby P. Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis [J]. J Lipid Res,2009,50 (Suppl):S352-357.
[3] Pedersen T R,Cater N B,Faergeman O,et al. Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction from the incremental decrease in end points through aggressive lipid lowering [IDEAL] trial [J]. Am J Cardiol,2010,106 (3):354-359.
[4] Cho E J,Min Y J,Oh M S,et al. Disappearance of angina pectoris by lipid-lowering in type III hyperlipoproteinemia [J]. Am J Cardiol,2011,107(5):793-796.
[5] Gracie J A,Robertson S E,Mclnnes I B. Interleukin-18[J]. J Leukoc Biol,2003,73(2):213-224.
[6] Mallat Z,Corbaz A,Scoazec A,et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability [J]. Circulation,2001,104(14):598-1603.
[7] Hong M K,Mintz G S,Lee C W,et al. Ruptures in stable angina pectoris compared with acute coronary syndrome[J]. Int J Cardiol,2007,114( 1):78-82.
[8] Xu S,Tang L,Mi Y, et al. Clinical significance of leukotriene b4 and extracellular matrix metalloproteinase inducer in acute coronary syndrome [J]. Clin Invest Med,2013,36(6):E282-289.
[9] Galis Z S,Khatri J J. Matrix metalloproteinases in vascular remodering and athrogenesis: the good,the bad,and the ugly[J]. Circ Res,2002,90(3):251-262.
[10] Kulach A,Dabek J,Glogowska-Ligus J,et al. Effects of standard treatment on the dynamics of matrix metalloproteinases gene expression in patients with acute coronary syndromes [J]. Pharmacol Rep,2010,62(6):1108-1116.
[11] Empana J P,Canoui-Poitrine F,Luc G,et al. Contribution of novel biomarkers to incident stable angina and acute coronary syndrome:the PRIME study [J]. Eur Heart J,2008,29(16):1966-1974.
[12] Nissen S E,Nichlls S J,Wolski K,et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial[J]. JAMA,2008,299(13):1561-1573.
[13] Ray K K,Cannon C P. The potential relevance of the multiple lipid- independent (pleiotropic) effects of statins in the management of acute coronary syndromes [J]. J Am Coll Cardiol,2005,46(8):1425-1433.
[14] Parthan A I,Leahy K J,O’Sullivan A K,et al. Cost effectiveness of targeted high-dose atorvastatin therapy following genotype testing in patients with acute coronary syndrome [J]. Pharmacoeconomics, 2013,31(6):519-531.
[15] Dabek J,Kulach A,Gasior Z. The role of matrix metalloproeinases in acute coronary syndromes[J]. Eur J Intern Med,2007,18 ( 6):463-466.
PDF(556 KB)
